{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:25:08Z","timestamp":1793053508168,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity-related heart failure with preserved ejection fraction (HFpEF) is increasingly recognised as a multiorgan cardio\u2013renal\u2013hepatic\u2013metabolic (CRHM) syndrome. Obesity promotes HFpEF through metabolic dysfunction, systemic inflammation, haemodynamic overload and ectopic adiposity. Increased visceral and epicardial fat has been linked with downstream involvement of the heart, liver and kidneys, resulting in a distinct phenotype with high symptom burden and functional limitation. Incretin based therapies such as glucagon-like peptide-1 receptor agonist (GLP-1 RA) are growing in popularity in CRHM conditions owing to positive effects on glycaemia, weight loss and systemic inflammation, leading to reduced adverse clinical outcomes. In obesity-related HFpEF, emerging data suggest GLP-1 RA and glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 agonists (also called incretin-based therapies) improve symptoms, exercise capacity, congestion, and reduce heart failure events, while also leading to reduced ectopic fat depositions in multiple organs and favourable cardiac remodelling. Incretin-based, weight-directed therapies therefore represent a promising strategy for a therapeutically challenging HFpEF phenotype. Future clinical trials incorporating multiorgan imaging endpoints across the heart, liver, adipose tissue and kidneys are needed to clarify the mechanisms of benefit and to better define the role of weight-reduction therapies in obesity-related HFpEF.<\/jats:p>","DOI":"10.1007\/s10741-026-10629-z","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:45:31Z","timestamp":1776048331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints"],"prefix":"10.1007","volume":"31","author":[{"given":"Masliza","family":"Mahmod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Wamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"9","key":"10629_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland IJ et al (2019) Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 7(9):715\u2013725","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10629_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP et al (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88","journal-title":"BMC Public Health"},{"issue":"36","key":"10629_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh T.A. et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"1","key":"10629_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M et al (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation 136(1):6\u201319","journal-title":"Circulation"},{"issue":"8","key":"10629_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Kitzman DW (2018) Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC Heart Fail 6(8):633\u2013639","journal-title":"JACC Heart Fail"},{"issue":"45","key":"10629_CR6","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1093\/eurheartj\/ehz713","volume":"40","author":"YNV Reddy","year":"2019","unstructured":"Reddy YNV et al (2019) The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J 40(45):3721\u20133730","journal-title":"Eur Heart J"},{"issue":"20","key":"10629_CR7","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 71(20):2360\u20132372","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10629_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-025-02606-x","volume":"24","author":"SS Khidr","year":"2025","unstructured":"Khidr SS et al (2025) Cardiac magnetic resonance quantified epicardial fat volume is associated with complex coronary artery disease among diabetics. Cardiovasc Diabetol 24(1):64","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10629_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ejhf.1167","volume":"20","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. Eur J Heart Fail 20(5):873\u2013878","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10629_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ et al (2025) Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers 11(1):14","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10629_CR11","first-page":"240","volume":"50","author":"P Kang","year":"2025","unstructured":"Kang P et al (2025) Perirenal Fat and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Blood Press Res 50(1):240\u2013248","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"10629_CR12","doi-asserted-by":"publisher","first-page":"109221","DOI":"10.1016\/j.isci.2024.109221","volume":"27","author":"L Wang","year":"2024","unstructured":"Wang L, Valencak TG, Shan T (2024) Fat infiltration in skeletal muscle: Influential triggers and regulatory mechanism. iScience 27(3):109221","journal-title":"iScience"},{"issue":"12","key":"10629_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41574-024-01041-4","volume":"20","author":"DCD Hope","year":"2024","unstructured":"Hope DCD, Tan TM (2024) Skeletal muscle loss and sarcopenia in obesity pharmacotherapy. Nat Rev Endocrinol 20(12):695\u2013696","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10629_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409\u20131439","journal-title":"Physiol Rev"},{"issue":"4","key":"10629_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756","journal-title":"Cell Metab"},{"issue":"24","key":"10629_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"11","key":"10629_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"3","key":"10629_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"issue":"12","key":"10629_CR19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN et al (2021) A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 384(12):1113\u20131124","journal-title":"N Engl J Med"},{"issue":"2","key":"10629_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V et al (2024) Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 391(2):109\u2013121","journal-title":"N Engl J Med"},{"issue":"4","key":"10629_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"19","key":"10629_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"10193","key":"10629_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"12","key":"10629_CR24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN et al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 389(12):1069\u20131084","journal-title":"N Engl J Med"},{"issue":"3","key":"10629_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","volume":"13","author":"MJ Davies","year":"2025","unstructured":"Davies MJ et al (2025) Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 13(3):196\u2013209","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10629_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M et al (2025) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 392(5):427\u2013437","journal-title":"N Engl J Med"},{"issue":"7","key":"10629_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM et al (2025) Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol 85(7):699\u2013706","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10629_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A et al (2021) Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 54(9):1150\u20131161","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10629_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R et al (2024) Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med 391(4):299\u2013310","journal-title":"N Engl J Med"},{"issue":"21","key":"10629_CR30","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ et al (2025) Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 392(21):2089\u20132099","journal-title":"N Engl J Med"},{"key":"10629_CR31","unstructured":"Food US, Administration D (2025) FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019. [cited 2026; Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash"},{"key":"10629_CR32","unstructured":"European Medicines Agency. Kayshild (semaglutide) (2025) [cited 2026; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kayshild"},{"issue":"1","key":"10629_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.kint.2025.10.005","volume":"109","author":"M Pruijm","year":"2026","unstructured":"Pruijm M et al (2026) REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int 109(1):6\u201316","journal-title":"Kidney Int"},{"issue":"1","key":"10629_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","volume":"22","author":"CM Kramer","year":"2020","unstructured":"Kramer CM et al (2020) Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 22(1):17","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"10629_CR35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jcmg.2013.11.011","volume":"7","author":"RV Shah","year":"2014","unstructured":"Shah RV et al (2014) Vasodilator stress perfusion CMR imaging is feasible and prognostic in obese patients. JACC Cardiovasc Imaging 7(5):462\u2013472","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"10629_CR36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/ehjci\/jeaa327","volume":"22","author":"P Doeblin","year":"2021","unstructured":"Doeblin P, Kelle S (2021) Cardiac magnetic resonance imaging: the echo of the obese? Eur Heart J Cardiovasc Imaging 22(5):528\u2013529","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"37","key":"10629_CR37","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA et al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"issue":"7","key":"10629_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","volume":"86","author":"O Gilbert","year":"2025","unstructured":"Gilbert O et al (2025) 2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 86(7):536\u2013555","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10629-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:53:40Z","timestamp":1781646820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10629-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10629"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10629-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interest: MM, AD and CL are employees of Perspectum, a company that develops medical imaging devices. MM also holds a Visiting Professorship at the University of Oxford. The remaining authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper. To minimise institutional bias, all imaging recommendations in this narrative review are based on vendor-neutral, widely adopted CMR, liver MRI and body-composition techniques, and we have cited standard measurement methods where available. No proprietary imaging sequences, software platforms or commercial services from Perspectum or any other vendor are named or promoted in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}